Myeloid-derived suppressor cells

By D. Gabrilovich. Cancer immunology research, 2017

959 citations recorded by the source corpus.

Myeloid cells developed evolutionarily as a major mechanism to protect the host. They evolved as a critical barrier against infections and are important contributors to tissue remodeling. However, in cancer, myeloid cells are largely converted to serve a new master—tumor cells. This process is epitomized by myeloid-derived suppressor cells (MDSC). These cells are closely related to neutrophils and monocytes. MDSCs are not present in the steady state of healthy individuals and appear in cancer and in pathologic conditions associated with chronic inflammation or stress. These cells have emerged as an important contributor to tumor progression. Ample evidence supports a key role for MDSCs in immune suppression in cancer, as well as their prominent role in tumor angiogenesis, drug resistance, and promotion of tumor metastases. MDSCs have a fascinating biology and are implicated in limiting the effects of cancer immunotherapy. Therefore, targeting these cells may represent an attractive therapeutic opportunity. Cancer Immunol Res; 5(1); 3–8. ©2016 AACR.

Subfields: Immunology, Neurology

View Paper: https://www.semanticscholar.org/paper/2dec09a161e0e9753d768c5950dae7b0695b72f5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. S. Grivennikov
2. F. Greten
3. Hugo Gonzalez
4. H. Nishikawa
5. J. Massagué
6. Zena Werb
7. E. Batlle
8. Y. Ohue

In Neurology

1. H. Nishikawa
2. J. Massagué
3. F. Greten
4. Zena Werb
5. E. Batlle
6. S. Grivennikov
7. Y. Ohue

Citations in the corpus

• Transforming Grown Factor-β Signaling in Immunity and Cancer (2019, positive): “80% of MDSCs display a polymorphonuclear phenotype (PMN-MDSCs) similar to that of neutrophils and can be recognized in flow cytometry analysis by the neutrophil surface marker combination CD11b +Ly6G+ (Coffelt et al., 2016; Gabrilovich, 2017).”
• Inflammation and Cancer: Triggers, Mechanisms and Consequences (2019, background): “…neutrophils via cytokine signaling or regulation of metabolism to further shape them to be anti-tumorigenic and antigen-presenting (Eruslanov et al., 2014), directly tumor-promoting (Nywening et al., 2018; Patel et al., 2018) or immunosuppressive (Gabrilovich, 2017; Veglia et al., 2019).”
• Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? (2019, background): “Control of PI(3) ki‐ nase in Treg cells maintains homeostasis and lineage stability.”
• Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “A population of cells phenotypically and morphologically similar to neutrophils, called polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), has been identified in cancer patients and preclinical models (for review, see Gabrilovich 2017).”